Bencini A F, Scaf A H, Sohn Y J, Meistelman C, Lienhart A, Kersten U W, Schwarz S, Agoston S
Anesth Analg. 1986 Mar;65(3):245-51.
The effect and plasma concentrations of vecuronium bromide were measured in normal patients after an intravenous dose of 50, 100, or 150 micrograms/kg and in patients with renal failure after 50 or 100 micrograms/kg. Urinary excretion of vecuronium was studied in normal patients after the 150 micrograms/kg dose. Pharmacokinetic parameters of patients with or without renal failure were similar. No metabolites of vecuronium were found in the plasma. Twenty percent of vecuronium was excreted unchanged in the urine; 5% as the 3-hydroxy derivative. No other metabolites of vecuronium were found in the urine. Increasing doses of vecuronium shortened the onset, but prolonged the duration of action and the recovery rate, to a similar extent in patients with or without renal failure. It was concluded that the disposition of vecuronium was best described by a three compartment model. Both the disposition and the effect of vecuronium are only marginally disturbed by renal failure.
对正常患者静脉注射50、100或150微克/千克维库溴铵后以及对肾衰竭患者静脉注射50或100微克/千克维库溴铵后，测定了维库溴铵的效应和血药浓度。对正常患者静脉注射150微克/千克剂量的维库溴铵后，研究了其尿排泄情况。有或无肾衰竭患者的药代动力学参数相似。血浆中未发现维库溴铵的代谢产物。20%的维库溴铵以原形经尿液排泄；5%以3-羟基衍生物形式排泄。尿液中未发现维库溴铵的其他代谢产物。增加维库溴铵剂量可缩短起效时间，但会延长作用持续时间和恢复时间，在有或无肾衰竭的患者中程度相似。得出的结论是，维库溴铵的处置情况可用三室模型最佳描述。肾衰竭对维库溴铵的处置和效应仅有轻微影响。
